CYTOMED
Cytomed is an innovative scientific-production pharmaceutical company.
CYTOMED
Industry:
Biopharma Medical Pharmaceutical
Founded:
1989-01-01
Status:
Active
Contact:
7 (812) 602-05-93
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Oftagest
Oftagest is an italian pharmaceutical company.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-03-20 | ONDOC | Cytomed investment in Seed Round - ONDOC | 1000 K USD |
More informations about "Cytomed"
Cytomed - Advancing
CytoMed's Technologies. CytoMed is translating its patent-pending technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based "off-the-shelf" immunotherapeutics for a wide range of cancers. CytoMed also engages in generating induced pluripotent stem cells (iPSCs) …See details»
About - Cytomed
CytoMed Therapeutics. Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) and focuses on …See details»
CytoMed Therapeutics - Crunchbase Company Profile & Funding
CytoMed Therapeutics is a spin-off from Singapore's Agency for Science, Technology, and Research (A*Star) that focuses on turning its patented technology into "off-the-shelf" …See details»
CytoMed Therapeutics : Organisation and personnel changes …
Dec 5, 2024 CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the …See details»
Cytomed Company Profile 2024: Valuation, Investors, Acquisition
Cytomed General Information Description. Developer of proprietary products for the treatment of inflammatory diseases. The company's products are used for the for the treatment of …See details»
Cytomed Therapeutics - Investor Relations
Nov 12, 2024 Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency …See details»
CytoMed, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore CytoMed, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 18 news, and 18 literature, Drug:Recombinant CD28(CytoMed, Inc.), CMI-206, CMI-568. ...See details»
Our Mission - Cytomed
Our Mission . To produce effective, more affordable cellular immunotherapies for solid and blood-based cancers. Who We Are Incorporated in 2018, CytoMed is a biotech company spun off …See details»
CytoMed Therapeutics
CytoMed Therapeutics. Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) and focuses on …See details»
Cytomed - Crunchbase Investor Profile & Investments
Cytomed is an innovative scientific-production pharmaceutical company. View contacts for Cytomed to access new leads and connect with decision-makers.See details»
Cytomed Therapeutics - CytoMed Therapeutics completes cash …
SINGAPORE, October 3, 2024 - CytoMed Therapeutics Limited (NASDAQ: GDTC) (CytoMed or Company), a Singapore-based biopharmaceutical company focused on harnessing its …See details»
Cytomed Therapeutics - A*STAR Spinoff CytoMed Therapeutics …
Jul 6, 2023 CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary …See details»
Cytomed - Crunchbase Company Profile & Funding
Organization. Cytomed . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. ... Cytomed is located in Dubai, Dubai, United Arab …See details»
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its …
Jul 6, 2023 Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency …See details»
CytoMed: Revolutionising CAR-T therapies - Research Features
Nov 29, 2023 CytoMed’s donor blood cell-derived CAR-γδ T cells and iPSC-derived γδ NKT cells may potentially become an ‘off-the-shelf’ cell therapy catering to a large pool of patients. …See details»
Manufacturer - Cytomed
CytoMed Therapeutics Limited (201808327H) Registered Office: 1 Commonwealth Lane #08-22, Singapore 149544. CytoMed Therapeutics (Malaysia) Sdn Bhd (1074609-M) Head Office & …See details»
CytoMed Therapeutics: Revolutionizing Cancer Treatment with …
Nov 12, 2024 Enter CytoMed Therapeutics Limited (NASDAQ: GDTC), a small-cap biotech company from Singapore that's revolutionizing cancer treatment through its groundbreaking …See details»
CytoMed (NASDAQ: GDTC): Revolutionizing Cancer Treatment …
Jun 28, 2023 According to the World Health Organization, there are more than 19.3 million new cancer cases each year, a number projected to rise to 29.5 million by 2040. This daunting …See details»
Pipeline - Cytomed
CytoMed Therapeutics Limited (201808327H) Registered Office: 1 Commonwealth Lane #08-22, Singapore 149544. CytoMed Therapeutics (Malaysia) Sdn Bhd (1074609-M) Head Office & …See details»
CytoMed Therapeutics Makes Strides in Cancer Treatment with …
Nov 20, 2024 In a remarkable leap forward for cutting-edge cancer treatment, CytoMed Therapeutics has embarked on its first-in-human Phase I ANGELICA clinical trial, focusing on …See details»